Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim

[1]  J. Bussel,et al.  Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up , 2014, Haematologica.

[2]  B. Chong,et al.  Results From a Phase IV Open-Label Study Evaluating Changes In Bone Marrow Morphology In Adult Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim: Analysis Of The 1- and 2-Year Romiplostim Cohorts , 2013 .

[3]  J. Viallard,et al.  An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim , 2013 .

[4]  D. Cines,et al.  Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials , 2013, European journal of haematology.

[5]  J. Bussel,et al.  Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy , 2013, British journal of haematology.

[6]  R. Brynes,et al.  A Longitudinal Prospective Study Evaluating the Effects of Eltrombopag Treatment On Bone Marrow in Patients with Chronic Immune Thrombocytopenia: Interim Analysis At 1 Year. , 2012 .

[7]  W. Langeberg,et al.  A Systematic Literature Review and Meta-Analysis of the Risk of Thromboembolic Events in Patients with Immune Thrombocytopenia (ITP) in Observational Studies. , 2012 .

[8]  H. Sørensen,et al.  Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population‐based cohort study , 2012, British journal of haematology.

[9]  K. Kirito,et al.  An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP) , 2012, International Journal of Hematology.

[10]  J. Sundquist,et al.  Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden , 2012, The Lancet.

[11]  M. Steurer,et al.  Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP), , 2011 .

[12]  Yow-Ming C Wang,et al.  A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. , 2011, Blood.

[13]  K. Kirito,et al.  Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial , 2011, International journal of hematology.

[14]  G. Molineux.  The development of romiplostim for patients with immune thrombocytopenia , 2011, Annals of the New York Academy of Sciences.

[15]  H. Sørensen,et al.  Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population‐based cohort study , 2011, British journal of haematology.

[16]  B. Chong,et al.  Romiplostim or standard of care in patients with immune thrombocytopenia. , 2010, The New England journal of medicine.

[17]  C. Enger,et al.  Comorbidities in patients with persistent or chronic immune thrombocytopenia , 2010, International journal of hematology.

[18]  J. Logie,et al.  Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database , 2010, Haematologica.

[19]  J. George,et al.  Evaluation of bleeding and thrombotic events during long‐term use of romiplostim in patients with chronic immune thrombocytopenia (ITP) , 2010, Journal of thrombosis and haemostasis : JTH.

[20]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[21]  B. Bain,et al.  Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. , 2009, Blood.

[22]  T. Nagasawa,et al.  A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura , 2009, International journal of hematology.

[23]  J. George,et al.  Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.

[24]  J. Stockman.  AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP , 2008 .

[25]  B. Bain,et al.  Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura. , 2006 .

[26]  J. Christal,et al.  An open‐label, unit dose‐finding study of AMG 531, a novel thrombopoiesis‐stimulating peptibody, in patients with immune thrombocytopenic purpura , 2006, British journal of haematology.

[27]  J. George,et al.  Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. , 1996, Blood.